Innovators in Cancer Immunology: Lung Cancer | Stories | PerkinElmer
PerkinElmer uses cookies to ensure that we give you the best experience possible on our website. This may include cookies from third party websites. If you continue without changing your settings, we will assume that you consent to receive cookies from this website. You can change your cookie settings at any time. To learn more, please review our cookie policy, which includes information on how to manage your cookies.

Innovators in Cancer Immunology: Lung Cancer

June 14, 2017



David L Rimm, MD, PhD
Professor of Pathology and of Medicine (Medical Oncology);
Director of Pathology Tissue Services;
Director of Translational Pathology
Yale University, New Haven, CT

To advance the understanding of disease mechanisms in cancer, it is critical that researchers see everything a tumor has to show them. Leveraging PerkinElmer’s Phenoptics Quantitative Pathology Research Solutions, researchers are now visualizing and measuring tumor cells and multiple immune-cell phenotypes simultaneously for the first time in formalin-fixed paraffin-embedded (FFPE) tissue.

Because of Phenoptics’ integration of multiplexed immunohistochemistry and imaging, leading scientists are now able to quantitatively capture systems biology data in cellular detail. What follows are brief profiles of some of these Innovators in Cancer Research and how they are using Phenoptics to discover new insights into the complexity of immune-cancer interactions that affect countless millions of patients around the world.

Dr. David Rimm, a pioneer of quantitative immunohistochemistry and inventor of AQUA® technology, focuses on predicting response to therapy in breast cancer and predicting recurrence or metastasis in melanoma and lung cancer. Dr. Rimm is working closely with PerkinElmer to bring rigor to the development of Phenoptics to make it a truly quantitative approach by helping to establish consistent Opal staining methods and expression measurement controls. He is particularly interested in exploring the per-cell and spatial parameters enabled by Phenoptics. Dr. Rimm’s first project evaluated Tumor Infiltrating Lymphocyte (TIL) status in a lung cancer Thrombotic Microangiopathy (TMA).

Read More Stories Like This One

Shelf Life: Take Control of Stability Testing

Typically, both drug substance and drug product are tested in at least two different storage conditions: long term ambient storage temperature and accelerated co...

GMP Compliance in QC Labs: It Takes a Village

Meeting standards for Good Manufacturing Practice (GMP) compliance is increasingly difficult for pharma labs. Regulatory bodies around the globe enforce these st...